Navigation Links
UC Davis researchers discover novel pathway to increased inflammation in diabetes patients
Date:11/27/2007

(SACRAMENTO, Calif.) -- Researchers at UC Davis Health System have discovered a novel pathway that results in increased inflammation of blood vessels in patients with type 1 diabetes. Their findings suggest that, with good diabetes control, this inflammation may be reduced, possibly resulting in a reduction of cardiovascular disease as well.

In a study now available both in the online edition of the Journal of Clinical Endocrinology & Metabolism as well on the National Institutes of Healths PubMed, the researchers provide the first-ever demonstration of increased expression and signaling in type 1 diabetics of two key receptors within the bodys innate immune system. Called TLR2 and TLR4, they are part of a family of pattern recognition receptors known as Toll-like receptors (TLRs), so-called because of their similarities to the well-defined Toll gene found in much-studied fruit flies.

Type 1 diabetes is a pro-inflammatory state associated with increased cardiovascular mortality. Inflammation plays a pivotal role in all stages of atherosclerosis, the progressive narrowing and hardening of the arteries over time. The UC Davis study found that TLR2 and TLR4 expression and signaling are increased in type 1 diabetes patients and contribute to the pro-inflammatory state.

It is not unreasonable to speculate that TLR2 and TLR4 promote atherogenesis by contributing to the pro-inflammatory state in type 1 diabetes, said lead author Ishwarlal Jialal, director of the Laboratory for Atherosclerosis and Metabolic Research and professor of internal medicine at UC Davis. Inflammation is central to heart disease, playing a pivotal role in plaque formation and stroke. We may well find that a serendipitous byproduct of controlling diabetes is the simultaneous control of this new pathway, leading to less inflammation and lower risk of heart problems.

The study represents the first-ever demonstration of increased TLR
'/>"/>

Contact: David Ong
david.ong@ucdmc.ucdavis.edu
916-734-9049
University of California - Davis - Health System
Source:Eurekalert

Page: 1 2

Related medicine news :

1. S.C. BlueCross Creates Corporate Planning Unit, Promotes Davis to Vice President
2. ABC TV San Francisco Features Canine Cancer Research Story: Saving Our Dogs, Helping Humans Beat Cancer - Work at Morris Animal Foundation, UC-Davis
3. After Dropping 162 Pounds, Jodi Davis Inspires Other Michigan Women to Get Moving and Lose Weight Through WalkyTalk.com(TM)
4. UC Davis researchers find evidence of mature heart cell potential in embryonic stem cells
5. Stanford researchers find culprit in aging muscles that heal poorly
6. UCLA researchers identify markers that may predict diabetes in still-healthy people
7. Mayo Clinic researchers discover new diagnostic test for detecting infection in prosthetic joints
8. Bipolar disorder relapses halved by Melbourne researchers
9. Cell that triggers symptoms in allergy attacks can also limit damage, Stanford researchers find
10. High and mighty: first common height gene identified by researchers behind obesity gene finding
11. Researchers estimate about 9 percent of US children age 8 to 15 meet criteria for having ADHD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... (GSA) the nation,s largest interdisciplinary organization devoted ... J. Jill Suitor, PhD, of Purdue University as ... to Gerontology Award. , This distinguished honor is ... have helped bring about a new synthesis and ... designs addressing a significant problem in the literature. ...
(Date:8/1/2014)... Gerontological Society of America (GSA) the ... aging has chosen Sean P. Curran, PhD, of ... of the Nathan Shock New Investigator Award. , This ... knowledge about aging through basic biological research. It was ... founding member of GSA and pioneer in gerontological research ...
(Date:8/1/2014)... Gerontological Society of America (GSA) the ... aging has chosen Carole B. Lewis, PT, DPT, ... recipient of the Excellence in Rehabilitation of Aging Persons ... acknowledge outstanding contributions in the field of rehabilitation. The ... or patient care, or publications that may include scholarly ...
(Date:8/1/2014)... Lifeinsurancenomedicalexam.info has released a new blog post explaining ... high cholesterol levels. , Clients who have a ... medical exam life insurance. These plans offer a convenient ... Since there are no medical examinations involved, clients who ... a few minutes. However, this convenience comes at a ...
(Date:8/1/2014)... August 01, 2014 Chilton Medical ... that aims to empower patients and their families ... health care by providing easy, secure access to ... patients instant, web-based access to their health information ... results, medications, allergies, demographic information, visit history, discharge/aftercare ...
Breaking Medicine News(10 mins):Health News:Suitor to receive GSA's 2014 Distinguished Career Contribution to Gerontology Award 2Health News:Curran to receive GSA's 2014 Nathan Shock New Investigator Award 2Health News:Lewis to receive GSA's 2014 Excellence in Rehabilitation of Aging Persons Award 2Health News:No Exam Life Insurance - Coverage for Clients Who Have High Cholesterol 2Health News:Chilton Medical Center Launches Online Patient Portal 2
... new project is an interdisciplinary research project covering ... has been awarded EUR 6 million from the ... The project will gather scientists from seven countries, ... University of Gothenburg, Sweden. , Those working on ...
... In the rat race of life, one thing is certain: ... in Molecular Ecology finds the same is true ... most form distinct neighborhoods where they spend the majority of ... lively neighborhoods each with its own personality. But scientists ...
... by Erich Lindemann Community Mental Health Education Center Initiative ... of Professional Psychology BOSTON, May 26 "The ... the needs of 1.5 million soldiers and marines and ... Estimates are as high as 33% that these ...
... connect using technology powered by 100 percent ... N.Y., May 26 Optimum Lightpath, a ... New York metropolitan area businesses, today introduced ... available exclusively through Optimum Lightpath to New ...
... Novel Oral Therapies Will Garner 29 Percent of the ... from Decision ResourcesWALTHAM, Mass., May 26 Decision Resources, ... for pharmaceutical and healthcare issues, finds that the approval ... as the increasing use of current and emerging injectable ...
... helps explain association between the two illnesses , , TUESDAY, ... gum disease (periodontitis) and heart disease has been discovered ... coronary heart disease (CHD) has been known for years, ... confirmed. The University of Kiel team found that the ...
Cached Medicine News:Health News:Sahlgrenska Academy to lead major European project on obesity 2Health News:Returning War Veterans: Challenges in Continuing Mental Health Care After Military and Civilian Trauma 2Health News:Returning War Veterans: Challenges in Continuing Mental Health Care After Military and Civilian Trauma 3Health News:Optimum Lightpath(SM) and GetWellNetwork(R) Transform Hospital Bedside Care with Launch of Interactive Patient Care Service 2Health News:Optimum Lightpath(SM) and GetWellNetwork(R) Transform Hospital Bedside Care with Launch of Interactive Patient Care Service 3Health News:Optimum Lightpath(SM) and GetWellNetwork(R) Transform Hospital Bedside Care with Launch of Interactive Patient Care Service 4Health News:Launch of Highly Anticipated Oral Agents and Increasing Use of Current and Emerging Injectable Drugs Will Drive the Multiple Sclerosis Drug Market to Nearly $10 Billion in 2018 2Health News:Launch of Highly Anticipated Oral Agents and Increasing Use of Current and Emerging Injectable Drugs Will Drive the Multiple Sclerosis Drug Market to Nearly $10 Billion in 2018 3Health News:Gum Disease, Heart Disease Share Genetic Link 2
(Date:7/31/2014)... , July 31, 2014 Lazarus Effect, ... novel interventional devices to facilitate removal of blood clots, ... from the financing will support EU commercialization of several ... for the Lazarus ReCover™ and Lazarus Cover™ in ... financing reflects investor confidence in the value of our ...
(Date:7/31/2014)... Catylix, Inc. ( Burbank, California ... California ) announced today the formation of ... fluorination products and related chemistry. Developing ... use of substituents that are chemically stable, resistant ... improve binding and bioavailability. Fluorinated functional groups are ...
(Date:7/31/2014)... -- Zacks.com announces the list of stocks featured in the Analyst ... latest news and events impacting stocks and the financial markets. ... BIIB - Free Report ), Gilead (Nasdaq: GILD - ... Report ), AbbVie (NYSE: ABBV - Free Report ) ... Today, Zacks is promoting its ,Buy, stock recommendations. ...
Breaking Medicine Technology:Lazarus Effect Closes $5 Million Financing 2Catylix, Inc. and Aspira Scientific Announce Joint Venture to Commercialize New Fluorination Technologies 2The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 2The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 3The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 4The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 5The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 6
... Phase III,clinical trial evaluating the efficacy and safety ... of postmenopausal osteoporosis were,presented at the American Society ... In the non-inferiority study comparing risedronate 150,mg once ... sodium,tablets)] increases in bone mineral density (BMD) were ...
... Sept. 19 Rockwell Medical,Technologies, Inc. (Nasdaq: ... and,developer of concentrates and specialty pharmaceuticals focused ... that it has commenced,enrollment in its Phase ... a physiological iron-maintenance therapy drug. The ...
Cached Medicine Technology:New Phase III Data Presented for Once Monthly Dosing Regimen of Risedronate to Treat Postmenopausal Osteoporosis 2New Phase III Data Presented for Once Monthly Dosing Regimen of Risedronate to Treat Postmenopausal Osteoporosis 3New Phase III Data Presented for Once Monthly Dosing Regimen of Risedronate to Treat Postmenopausal Osteoporosis 4New Phase III Data Presented for Once Monthly Dosing Regimen of Risedronate to Treat Postmenopausal Osteoporosis 5New Phase III Data Presented for Once Monthly Dosing Regimen of Risedronate to Treat Postmenopausal Osteoporosis 6Rockwell Medical Technologies, Inc. Begins Patient Enrollment for its SFP Dose-Ranging Study 2Rockwell Medical Technologies, Inc. Begins Patient Enrollment for its SFP Dose-Ranging Study 3Rockwell Medical Technologies, Inc. Begins Patient Enrollment for its SFP Dose-Ranging Study 4
... designed to validate HDL cholesterol plus other ... This control is compatible with most major ... Synchron and Vitros. HDL values are given ... methods: Dextran Sulfate 50,000 MW. Apolipoprotein A-1 ...
... is intended as a means ... ethanol assay methods. This ready-to-use, ... clinically significant levels of ammonia ... provided for the following instruments: ...
... This unassayed control is intended ... manual and automated assay methods ... oxalate in human urine samples. ... requiring no reconstitution. This control ...
... Microbumin is a two-level control ... Clinitek Microalbumin Reagent Strips and Roche ... also suitable for turbidimetric immunoassays using ... and DCA 2000, Cobas, Diasorin SPQ ...
Medicine Products: